Mini-symposium on quantum technology - pioneering collaboration between UKF and Pfizer
Contents
The symposium spanned the spectrum from basic research through clinical and applied research to industrial applications. The following topics were discussed in three discussion rounds, each of which was introduced by an impulse from the UKF and Pfizer:
Round 1: Opportunities and limits of quantum computing for basic research, personalised medicine and prevention: Prof. Dr. Michael Köttgen (UKF) & Dr. med. Christian Lenz (Pfizer) as initiators
Round 2: Quantum computing in real life and in applied research: Prof Dr Andy Maun (UKF) & Dr Frederic Kube (Pfizer) as driving forces
Round 3: Applications in pharmaceutical production and in the field of personalised diagnostics in oncology: Peter Neske (Pfizer) &; Prof. Dr Tonio Ball (UKF and NeuroMentum AI) as a driving force
In particular, the outstanding experience report on AI-Q Phase 1 "AI-Q Quantum Diamond Platform for an Improved HER2-Targeting of Antibody-Drug-Conjugate (ADC) Therapies" (Prof Tonio Ball) highlighted great potential.
Outlook
The lively discussion showed a great common interest in building strategic resources and a strong community in the future field of quantum technology. It was also emphasised that interdisciplinary collaboration between clinics, research and industry is a prerequisite for successfully addressing complex topics such as AI and sensor technology.
This symposium is intended to be the starting point for further formats that promote the use of quantum technology for diagnostics and therapy. The collaboration between UKF and Pfizer will be further strengthened on this innovative basis.
Participating players
University Medical Centre Freiburg, Pfizer Pharma GmbH, NeuroMentum AI, FWTM, University of Freiburg, BadenCampus, Fraunhofer IAF, Fraunhofer IAO, QuantumBasel, QAI Ventures, BIOPRO BW GmbH, IHK Südlicher Oberrhein, QuantumBW, DE:Hub 5 HT, Kipu Quantum GmbH, Mertelsmann Foundation, Roland Berger GmbH
Significance and goal
In the form of a mini-symposium, representatives of a multidisciplinary audience of experts discussed the application of quantum technology in research, clinics and industry. The symposium is considered a milestone in the growing industry-on-campus cooperation between UKF and Pfizer.
The aim of the mini-symposium was to shed light on current and potential applications of quantum technology in medicine and discuss them from a multidisciplinary perspective, as well as to identify specific points of contact for research and clinical practice.